Uncategorized Archives - BioMedWire (BMW)

WednesdayNov 04, 2026 10:30 am

Adaptogenics Health Corp. (CSE: ADPT) Eyes Opportunities Beyond Standard Peptides as Policy Opens Pharmacy and Telehealth Channels

Disseminated on behalf of Adaptogenics Health Corp.and may include paid advertising. The federal government is working on an interim peptide access policy that would let specialty pharmacies to produce certain peptides while formal rulemaking proceeds. Adaptogenics plans to develop delivery technologies to improve the stability, exposure, administration and performance of selected peptides. The company has also acquired nutritional research assets developed by Berkwood Research to support a GLP-1 companion initiative. U.S. Health Secretary Robert F. Kennedy Jr. has made his view plain. Americans, he said, are going to buy peptides anyway, so the government should make sure they come from…

WednesdayNov 04, 2026 9:45 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Broad Strategy Anchored by Science, Disciplined Growth

The scale of the need for neurological solutions is enormous; the World Health Organization reports that more than three billion people live with a neurological condition. Quantum focuses on neurodegenerative, metabolic and alcohol misuse disorders, pursuing a strategy that pairs pharmaceutical research with commercialization partnerships and licensing structures designed to support multiple potential revenue streams. The most advanced piece of the neurodegenerative strategy is Lucid-MS, a patented new chemical entity designed to address demyelination. Brain disorders touch more lives than almost any other area of medicine, yet they remain among the hardest to treat. Quantum BioPharma (NASDAQ: QNTM) is taking on…

TuesdayNov 03, 2026 10:00 am

Scientists Develop Experimental Method Leveraging Ultrasound to Treat Brain Cancer

University of Virginia researchers have developed an experimental method that uses ultrasound to deliver therapeutic nanoparticles into the brain in order to fight glioblastoma, a deadly brain cancer. The study team, which was led by Prof. Roger Abounader, designed a treatment approach that combined the use of ultrasound, nanoparticles, as well as microRNA (small RNA molecules that regulate gene activity). Their method proved promising as a new way to treat this deadly brain cancer. The tiny gene molecules they used were selected because they have the potential to disrupt multiple tumor cell mechanisms. Each component of their experimental treatment method…

TuesdayNov 03, 2026 9:00 am

Earth Science Tech Inc. (ETST) Wins Through the Inherent Operating Leverage of Its ‘Conglomerate’ Business Model

Earth Science Tech’s ‘conglomerate’ business model has allowed it to leverage its internal tech stack, real estate, as well as ingredient-sourcing and manufacturing capabilities to capture the profit margins at every step that other companies are forced to outsource The company is focused on building a vertically integrated healthcare platform that combines compounding pharmacy operations, telemedicine platforms, clinical support, and direct-to-patient fulfillment Earth Science Tech now augments its healthcare operations through investments in real estate, asset management activities, and consumer products business Earth Science Tech (OTCQB: ETST) is a strategic holding company that brings together innovative businesses across the healthcare,…

MondayNov 02, 2026 11:15 am

Adaptogenics Health Corp. (CSE: ADPT) Targets Supply, Verification, Traceability in Emerging Peptide Market

Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising. The movement toward a regulated peptide market is increasing its momentum. A responsible peptide market needs four things: dependable supply, documented traceability, independent verification and better products grounded in evidence. Better products are the longer-term goal, and Adaptogenics’ research programs will be built around defined biological endpoints and development milestones. Peptides are moving from the fringes of wellness culture toward the regulated pharmacy counter. Whether that shift protects patients will depend on something less visible than policy: proof of what is actually in each vial. Adaptogenics Health (CSE:…

MondayNov 02, 2026 10:30 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) Draws ‘Men’s Fitness’ Spotlight as Unbuzzd Trial Shows Early Promise

Earlier this month, “Men’s Fitness,” reviewed the unbuzzd clinical trial and described the early study findings as “promising.” Results showed that estimated blood alcohol concentration was significantly lower and participants experienced improved self-rated alertness and lower headache severity. For operators in this space, the stakes reach beyond the morning after. Most recovery drinks promise relief after a night out, yet few have been tested against a placebo in a registered human trial. One that has is now getting a close look from a major fitness publication. Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company developing therapies for neurodegenerative, metabolic and alcohol misuse disorders,…

ThursdayOct 29, 2026 10:30 am

Oncotelic Advances PLA from Published Liver Cancer Findings Toward 100 Billion Protein Vectors

PLA gives overlooked biological evidence its own analysis before combining the findings. Published HCC research connects PLA-guided investigation with a four-gene survival signature validated in an independent patient cohort. As Anthropic and OpenAI expand biological discovery with AI agents, Oncotelic is targeting a 100-billion-vector protein program. Oncotelic Therapeutics Inc. (OTCQB: OTLC) is building its PDAOAI drug discovery engine around a compelling premise: a clue buried in a small corner of the literature can redirect an entire research program. Its Partitioned Literature Aggregation (“PLA”) algorithm is designed to uncover those clues. A liver-cancer study published in Biomedicines on October 23, 2026,…

ThursdayOct 29, 2026 10:00 am

Universal Healthcare Could Be a Key Issue During the Midterms

Abdul El-Sayed, a Democrat vying to win a U.S. Senate seat in Michigan, has become a nationally renowned figure after he built his campaign around advocating for a single payer healthcare system, popularly known as Medicare for all. During a recent campaign tour, he was accompanied by Democratic firebrand Alexandria Ocasio-Cortez (AOC). The animated crowds that attended all their rallies pose the question, is universal healthcare going to be a deciding factor as to who wins different races during the midterms next week? It isn’t easy to say, because there are many nuances to the issue. For starters, universal healthcare…

FridayOct 23, 2026 9:00 am

Why Adaptogenics Health Corp. (CSE: ADPT) Is ‘One to Watch’

Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertisements. Adaptogenics is pursuing three complementary opportunities across pharmaceutical-quality peptide supply, proprietary therapeutics and next-generation delivery technologies. Its planned supply network could generate commercial revenue while supporting therapeutic development through external manufacturing and laboratory partners. The company is targeting metabolic health, muscle preservation, mitochondrial function, recovery and healthy ageing through proprietary peptide and small-molecule therapeutics. CEO Dr. J. David Warren brings a scientific record that includes 17 issued patents, while President Antoun Nabhan brings experience spanning more than $2 billion in healthcare transactions and two Nasdaq IPO processes. Adaptogenics…

ThursdayOct 22, 2026 9:45 am

Durability as the New Standard in Cartilage Repair: Why Long-Term Results Are Reshaping Global Orthopedics

Orthopedic care is increasingly focused not only on relieving symptoms, but on delivering durable outcomes that can stand up over time. That shift is creating greater interest in regenerative approaches designed to restore damaged tissue rather than simply address the immediate effects of injury. Regentis Biomaterials is advancing this approach with GelrinC, a degradable hydrogel implant designed to support the regeneration of durable cartilage in the knee. Orthopedic medicine has long focused on relieving pain and restoring mobility. Increasingly, though, the question is: How well will the result hold up over time? That question is particularly important in cartilage repair.…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Adaptogenics Health Corp. (CSE: ADPT) Eyes Opportunities Beyond Standard Peptides as Policy Opens Pharmacy and Telehealth Channels

Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Broad Strategy Anchored by Science, Disciplined Growth

Scientists Develop Experimental Method Leveraging Ultrasound to Treat Brain Cancer

Earth Science Tech Inc. (ETST) Wins Through the Inherent Operating Leverage of Its ‘Conglomerate’ Business Model

Adaptogenics Health Corp. (CSE: ADPT) Targets Supply, Verification, Traceability in Emerging Peptide Market

Quantum BioPharma Ltd. (NASDAQ: QNTM) Draws ‘Men’s Fitness’ Spotlight as Unbuzzd Trial Shows Early Promise

Oncotelic Advances PLA from Published Liver Cancer Findings Toward 100 Billion Protein Vectors

Universal Healthcare Could Be a Key Issue During the Midterms

Why Adaptogenics Health Corp. (CSE: ADPT) Is ‘One to Watch’

Durability as the New Standard in Cartilage Repair: Why Long-Term Results Are Reshaping Global Orthopedics

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search